Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
PHILADELPHIA and OXFORD, United Kingdom, Feb. 03, 2016 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that James Noble, Chief Executive Officer of Adaptimmune, will present at the following two conferences, both being held at the Waldorf Astoria in New York City:
- The 2016 BIO CEO & Investor Conference on Tuesday February 9, 2016 at 9:00AM ET (2:00 PM GMT); and
- The Leerink Partners 5th Annual Global Healthcare Conference on Wednesday February 10, at 8:25 AM ET (1:25 PM GMT).
Adaptimmune’s presentations will be webcast live for investors through the investor section of www.adaptimmune.com and available for a period of 30 days following the conference.
About Adaptimmune
Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor (TCR) platform. Established in 2008, the company aims to utilize the body’s own machinery - the T-cell - to target and destroy cancer cells by using engineered, increased affinity TCRs as a means of strengthening natural patient T-cell responses. Adaptimmune’s lead program is an affinity enhanced T-cell therapy targeting the NY-ESO cancer antigen. Its NY-ESO TCR affinity enhanced T-cell therapy has demonstrated signs of efficacy and tolerability in Phase 1/2 trials in solid tumors and in hematologic cancer types, including synovial sarcoma and multiple myeloma. In June 2014, Adaptimmune announced that it had entered into a strategic collaboration and licensing agreement with GlaxoSmithKline (GSK) for the development and commercialization of the NY-ESO TCR program in partnership with GSK. In addition, Adaptimmune has a number of proprietary programs. The company has identified over 30 intracellular target peptides preferentially expressed in cancer cells and is currently progressing 12 through unpartnered research programs. Adaptimmune has over 200 employees and is located in Oxfordshire, U.K. and Philadelphia, USA. For more information: http://www.adaptimmune.com
Adaptimmune Contacts Will Roberts Vice President, Investor Relations T: (215) 825-9306 E: [email protected] Margaret Henry Head of PR T: +44 (0)1235 430036 Mob: +44 (0)7710 304249 E: [email protected]
